A detailed history of Telemetry Investments, L.L.C. transactions in Bellerophon Therapeutics, Inc. stock. As of the latest transaction made, Telemetry Investments, L.L.C. holds 44,000 shares of BLPH stock, worth $440. This represents 0.06% of its overall portfolio holdings.

Number of Shares
44,000
Previous 47,500 7.37%
Holding current value
$440
Previous $52,000 23.08%
% of portfolio
0.06%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.67 - $1.2 $2,345 - $4,200
-3,500 Reduced 7.37%
44,000 $40,000
Q3 2022

Nov 17, 2022

SELL
$0.96 - $1.69 $20,640 - $36,335
-21,500 Reduced 31.16%
47,500 $52,000
Q2 2022

Aug 15, 2022

SELL
$0.85 - $2.36 $12,396 - $34,418
-14,584 Reduced 17.45%
69,000 $85,000
Q1 2022

May 16, 2022

SELL
$1.82 - $3.24 $34,938 - $62,198
-19,197 Reduced 18.68%
83,584 $197,000
Q4 2021

Feb 14, 2022

BUY
$2.36 - $4.05 $40,783 - $69,988
17,281 Added 20.21%
102,781 $319,000
Q3 2021

Nov 15, 2021

SELL
$3.75 - $4.86 $20,325 - $26,341
-5,420 Reduced 5.96%
85,500 $347,000
Q2 2021

Aug 16, 2021

BUY
$3.83 - $5.65 $114,432 - $168,810
29,878 Added 48.95%
90,920 $440,000
Q1 2021

May 17, 2021

SELL
$5.07 - $8.27 $151,298 - $246,793
-29,842 Reduced 32.84%
61,042 $317,000
Q4 2020

Feb 16, 2021

SELL
$6.12 - $10.37 $160,711 - $272,316
-26,260 Reduced 22.42%
90,884 $606,000
Q3 2020

Nov 16, 2020

SELL
$9.27 - $13.79 $72,825 - $108,334
-7,856 Reduced 6.28%
117,144 $1.19 Million
Q2 2020

Aug 14, 2020

BUY
$9.43 - $20.28 $707,250 - $1.52 Million
75,000 Added 150.0%
125,000 $1.57 Million
Q1 2020

May 15, 2020

BUY
$3.39 - $18.0 $169,500 - $900,000
50,000 New
50,000 $548,000

Others Institutions Holding BLPH

# of Institutions
1
Shares Held
44K
Call Options Held
0
Put Options Held
0

About Bellerophon Therapeutics, Inc.


  • Ticker BLPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,545,450
  • Market Cap $95.5K
  • Description
  • Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development...
More about BLPH
Track This Portfolio

Track Telemetry Investments, L.L.C. Portfolio

Follow Telemetry Investments, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemetry Investments, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Telemetry Investments, L.L.C. with notifications on news.